NKG2A Expression among CD8 Cells Is Associated with COVID-19 Progression in Hypertensive Patients: Insights from the BRACE CORONA Randomized Trial

Renata Moll-Bernardes 1,2, Sérgio C. Fortier 1,2, Andréa S. Sousa 1,3, Renato D. Lopes 1,4,5, Narendra Vera 6, Luciana Conde 6, André Feldman 1,7, Guilherme Arruda 1,8, Mauro Cabral-Castro 9, Denílson C. Albuquerque 1,10, Thiago C. Paula 1,11, Thyago Furquim 1,12, Vitor A. Loures 1,7, Karla Giusti 1,13, Nathália Oliveira 1,13, Ariane Macedo 1,11,14, Pedro Barros e Silva 5, Fábio De Luca 1,15, Marisol Kotsugai 1,15, Rafael Domiciano 1,17, Flávia A. Silva 1,2, Mayara F. Santos 1,16, Olga F. Souza 1,16, Fernando A. Bozza 1,3, Ronir R. Luiz 1,17,† and Emiliano Medei 1,6,18,‡

1 D’Or Institute for Research and Education, Rio de Janeiro 22281-100, Brazil; renata.moll@idor.org (R.M.-B.); sergiofortier@gmail.com (S.C.F.); andreasilvestroz203@gmail.com (A.S.S.); renato.lopes@duke.edu (R.D.L.); andre.feldman@hotmail.com (A.F.); guilherme.arruda@sao.luiz.com.br (G.A.); denilson.albuquerque@idor.org (D.C.A.); sopconstar@gmail.com (T.C.P.); thyago.furquim@sao.luiz.com.br (T.F.); vitor.aloures@sao.luiz.com.br (V.A.L.); karlagouveia@yahoo.com.br (K.G.); nathalia.m.oleireira@hospitalvilalobos.com.br (N.O.); arianevim@yahoo.com.br (A.M.); deluca.cardio@gmail.com (F.D.L.); marisol.dorizo@sao.luiz.com.br (M.K.); rafael.domiciano@sao.luiz.com.br (R.D.); famoroso.ms@gmail.com (F.A.S.); mayara.fraga@idor.org (M.F.S.); olga.souza@rededor.com.br (O.F.S.); bozza.fernando@gmail.com (F.A.B.); ronir@iesc.ufrj.br (R.R.L.)
2 Pathological Anatomy Laboratory, Rede D’Oro Luiz, São Paulo 04321-120, Brazil
3 Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro 21040-360, Brazil
4 Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
5 Brazilian Clinical Research Institute, São Paulo 01404-000, Brazil; drpedrobarros80@gmail.com
6 Institute of Biophysics Carlos Chagas Filho, Federal University of Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; vera.narendra@gmail.com (N.V.); lucianaconde@biof.ufrj.br (L.C.)
7 São Luiz Anália Franco Hospital, São Paulo 03313-001, Brazil
8 São Luiz Caetano Hospital, São Caetano do Sul 09531-205, Brazil
9 Institute of Microbiology Paulo de Góes, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil; maurojorge@micro.ufrj.br
10 Cardiology Department, Hospital de São Paulo, São Paulo 01500-020, Brazil
11 São Luiz Jabaquara Hospital, São Paulo 04321-120, Brazil
12 Sino Brasileiro Hospital, Osasco 06016-050, Brazil
13 Villa Lobos Hospital, São Paulo 03814-020, Brazil
14 Santa Casa de São Paulo, São Paulo 01221-010, Brazil
15 São Luiz Morumbi Hospital, São Paulo 05605-050, Brazil
16 Copa Star Hospital, Rio de Janeiro 22031-012, Brazil
17 Public Health Studies Institute—IESC, Federal University of Rio de Janeiro, Rio de Janeiro 21941-592, Brazil
18 National Center for Structural Biology and Bioimaging, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil
† These authors contributed equally to this work.
‡ Correspondence: emedei70@biof.ufrj.br; Tel.: +55-21-3938-0370

Abstract: Cardiovascular comorbidities and immune-response dysregulation are associated with COVID-19 severity. We aimed to explore the key immune cell profile and understand its association with disease progression in 156 patients with hypertension that were hospitalized due to COVID-19. The primary outcome was progression to severe disease. The probability of progression to severe disease was estimated using a logistic regression model that included clinical variables and immune cell subsets associated with the primary outcome. Obesity; diabetes; oxygen saturation; lung involvement on computed tomography (CT) examination; the C-reactive protein concentration; total lymphocyte count; proportions of CD4+ and CD8+ T cells; CD4/CD8 ratio; CD8+ HLA-DR MFI; and CD8+ NKG2A MFI on admission were all associated with progression to severe COVID-19. This study demonstrated that increased CD8+ NKG2A MFI at hospital admission, in combination...
with some clinical variables, is associated with a high risk of COVID-19 progression in hypertensive patients. These findings reinforce the hypothesis of the functional exhaustion of T cells with the increased expression of NKG2A in patients with severe COVID-19, elucidating how severe acute respiratory syndrome coronavirus 2 infection may break down the innate antiviral immune response at an early stage of the disease, with future potential therapeutic implications.

Keywords: COVID-19; NKG2A; HLA-DR; T cell; hypertension; immune response

1. Introduction

Risk factors such as hypertension, diabetes, older age and obesity have been associated with worse prognosis in patients with coronavirus disease 2019 (COVID-19). Among these, hypertension is particularly important due to its high prevalence and global burden, however, the mechanisms of this association have not been fully clarified [1–5].

Previous studies emphasized the role of inflammation in the pathogenesis of hypertension [6]. Various subsets of immune cells such as B and T lymphocytes that are involved in innate and adaptive immune responses are implicated in vascular injury in hypertension [7]. Likewise, a dysregulated immune response has been described as a hallmark of severe COVID-19 and is associated with the progression to acute respiratory distress syndrome and death [8–11]. Thus, research groups have made significant efforts to determine the role of immune cells in COVID-19 [12–14].

One of the most recurrent events that is observed in COVID-19 is robust lymphopenia [15]. Decreases in all lymphocytes, including T, B, and natural killer (NK) cells, have been reported in patients with this disease [12]. This immunological profile is strongly associated with disease severity [16]. In addition, Zheng et al. [17] reported an increased expression of CD94/natural killer group 2 member A (NKG2A) receptor in patients that were infected with SARS-CoV2.

NKG2A is a member of the C-type lectin-like receptor superfamily, and this inhibitory receptor is known to be present in several immune cells, including CD8 cells. These lymphocytes mediate immunosurveillance against viral infection and virus-induced neoplasia [18,19]. According to Zheng [17] an increased expression of NKG2A may be associated with COVID-19 progression, and the downregulation of NKG2A expression may correlate with disease recovery. These findings suggest that the functional exhaustion of cytotoxic lymphocytes is associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Hence, SARS-CoV-2 infection may break down antiviral immunity at an early stage.

To our knowledge, there is no previous publication analyzing immune cell subsets in such a large number of hypertensive patients with COVID-19. In this study, we aimed to better understand which immune cell subtypes are associated with more severe disease in this group of patients and explore the physiopathology of the immune response in COVID-19.

2. Materials and Methods

2.1. Population and Design

Patients that were included in this study were part of the BRACE CORONA trial [20], an investigator-initiated, phase-IV, multicenter, open-label, registry-based randomized trial involving 659 patients on angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs) with confirmed COVID-19, who were hospitalized at 29 centers in Brazil. The present study was a secondary analysis conducted with blood samples from 156 hospitalized patients with hypertension that were enrolled consecutively in the trial at six centers in the state of São Paulo, Brazil. The samples were collected within 72 h of hospital admission, after COVID-19 diagnosis confirmation, between 21 May and 27 June 2020. The trial protocol [21] was approved by the Brazilian Ministry of Health’s
National Commission for Research Ethics and by the institutional review boards or ethics committees of participating sites. All patients provided informed consent before enrollment.

Patients that were eligible for the BRACE CORONA trial were aged ≥18 years and were on treatment with ACEI/ARB at baseline. Patients with clinical indications for ACEI/ARB treatment termination on admission, such as hypotension, acute kidney injury, and/or shock, were excluded. Patients on mechanical ventilation and those with hemodynamic instability, acute renal failure, or shock on admission were also excluded [20]. The inclusion and exclusion criteria are provided in detail in the Supplementary Materials.

2.2. Outcomes

The primary outcome was progression to severe disease, according to the modified World Health Organization (WHO) Ordinal Scale for Clinical Improvement, during hospitalization. The scores on this scale range from 0 (no evidence of infection) to 8 (death); disease was classified as non-severe (mild to moderate, scores of 3–5), ranging from the lack of need for oxygen therapy to conditions requiring noninvasive ventilation, and severe (scores of 6–8), including disease requiring mechanical ventilation, inotropic support, and/or renal replacement therapy, and that caused death (Table S1) [22]. Secondary outcomes were the lengths of stay (LOSs) in the hospital and intensive care unit (ICU), acute myocardial infarction, new or worsening heart failure, hypertensive crisis, transient ischemic attack, stroke, myocarditis, pericarditis, arrhythmia requiring treatment, and thromboembolic events.

2.3. Clinical and Laboratory Data

Baseline patient characteristics were assessed on admission and included sex, age, and oxygen saturation, as well as the extent of lung involvement on computed tomography (CT) examination and C-reactive protein (CRP) level, measured by latex-enhanced immunoturbidimetric assay. Comorbidities, including obesity, diabetes, asthma, chronic obstructive pulmonary disease, dyslipidemia, and coronary artery disease, were also recorded on admission. The criteria that were used for the identification of these complications have been provided in the BRACE-CORONA trial report [21].

2.4. Peripheral Blood Mononuclear Cell Isolation

Blood samples were collected from the patients into ethylenediamine-tetraacetic acid (EDTA) tubes (BD Vacutainer® spray-coated K2EDTA Tube, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), which were centrifuged at 1500 × g for 15 min at 21 °C. Lymphocytes and monocytes were quantified in an automated ABX Micros 60 system (Horiba Medical, Montpellier, France) using photometry. To obtain peripheral blood mononuclear cells (PBMCs), density gradient centrifugation (Ficoll-Paque, GE Healthcare, Piscataway, NJ, USA) was performed. The samples were then processed. One milliliter of phosphate-buffered saline (PBS) was added to each original tube. To a separate 50-mL Falcon tube, 9 mL of Ficoll-Paque PLUS (GE Healthcare) and the same amount of PBS were added. The blood solution was transferred to the Ficoll-Paque tube slowly to separate the layers. This was centrifuged continuously at 18–20 °C and 830 × g for 15 min. Then, the buffy coat was transferred to a new 50-mL Falcon tube and PBS was added to a volume of 10 mL, followed by homogenization. The tube was centrifuged continuously at 830 × g for 8 min, the supernatant was removed, and the pellet was resuspended by tapping the tube with PBS to a volume of 10 mL. The tube was then centrifuged at 890 × g for 5 min, the supernatant was removed, and the pellet was resuspended by tapping the tube with Roswell Park Memorial Institute (RPMI) medium to a volume of 10 mL. The tube was centrifuged at 890 × g for 5 min, the supernatant was removed, and the process was repeated. The obtained PBMCs were frozen at –80 °C in a solution containing 400 µL of fetal bovine serum (FBS), 400 µL of RPMI medium, and 200 µL of dimethyl sulfoxide.

The cryopreserved PBMC samples were removed from the freezer and thawed rapidly in a 37 °C water bath. They were then transferred to a 15-mL Falcon tube, and RPMI
medium with 10% FBS was added drop by drop while mixing slowly. One to two drops were added every 10 s; when the solution reached the volume of 2 mL, RPMI medium was added to a final volume of 10 mL. The cells were washed twice with RPMI medium with 10% FBS with centrifugation at 840 × g for 5 min at room temperature.

2.5. Flow Cytometry
To quantify the immune cell populations in the PBMCs, 1 × 10^6 cells were stained with various combinations of fluorophore-conjugated antibodies (Table S2). After incubation and washing, the samples were analyzed by flow cytometry in a BD FACS Canto II apparatus (Becton Dickinson, San Jose, CA, USA) using the BioConductor R packages (bioconductor.org; accessed on 15 October 2021) at the Pathology Laboratory of Rede D’Or São Luiz hospitals. The technical procedures and flow cytometry followed the laboratory’s previously validated standards. All fluorochrome-conjugated antibodies were validated before use, with determination of the reaction specificity and best volume for antigen–antibody-binding saturation (titration). The following profiles were quantified: total monocytes; total lymphocytes; B lymphocytes; T lymphocytes; NK cells; CD4+ T cells; CD8+ T cells; CD4/CD8 relationship; CD8+ CD38+ T cells (percentage and CD38 mean fluorescent intensity–(MFI)); CD8+ HLA-DR+ T cells (percentage and HLA-DR MFI); CD8+ NKG2A+ T cells (percentage and NKG2A MFI); CD8+ HLA-DR+ CD38- T cells; CD8+ HLA-DR+ CD38+ T cells; CD8+ HLA-DR- CD38+ T cells; and CD8+ HLA-DR- CD38- T cells. The approximate membrane expression (MFI) of the antigens HLA-DR and CD38, important markers of T-cell activation, and of NKG2A, an inhibitory receptor of T cells, were evaluated to improve the understanding of lymphocyte properties.

2.6. Statistical Analysis
Continuous variables were described as medians, means, and standard deviations; categorical variables were characterized as proportions. For the primary outcome, 95% confidence intervals (CIs) were calculated. Fisher’s exact test was used to detect the statistical associations between the outcome and categorical clinical variables. For continuous variables, receiver operating characteristic curves were used to evaluate associations with disease progression. Biomarkers that were associated significantly with the primary outcome were dichotomized using cutoff points of 90% sensitivity.

To better understand the associations of immune cell profiles and clinical variables with the risk of COVID-19 progression, a forward stepwise predictive multiple model was proposed. Due to the large number of biomarkers, a preliminary univariate analysis selected those that were associated with the outcome with areas under receiver operating characteristic curves (AUCs) > 0.65. These selected biomarkers with higher potential predictive value were combined with clinical variables and included in the model. The significance level for the entry and removal of the variables that were selected by automatic regression was set to 5%. Beta coefficients and odds ratios (ORs) were calculated for all variables in each step of the model to quantify associations with the outcome. The goodness of fit of the final model was evaluated by the Hosmer–Lemeshow test. Predicted probabilities of the primary outcome were estimated using variables with significant associations in the final model. All analyses were performed using SPSS software (version 24.0; IBM Corporation, Armonk, NY, USA).

3. Results
The mean patient age was 53.8 ± 12.2 years, and 54 (34.6%) patients were female. Among the 156 hypertensive patients, 12.2% were using ACEIs and 87.8% were using ARBs. Regarding comorbidities, 81 (51.9%) had obesity, 40 (25.7%) had diabetes, and 25 (16%) had dyslipidemia; two (1.3%) patients had heart failure and three (1.9%) had coronary artery disease. Asthma was reported in three (1.9%) cases, and chronic pulmonary and chronic renal disease were each reported in 1.3% of cases (Table 1). Five of 156 patients (3.2%) were
using glucocorticoids before hospital admission. Data on all comorbidities are provided in Figure S1.

Table 1. Baseline patient characteristics according to progression to severe disease *.

| Clinical Conditions                  | Total (n = 145/156) | Non-Severe Cases (n = 145/156) | Severe Cases * (n = 11/156) | Fisher’s Exact Test p-Value |
|-------------------------------------|---------------------|-------------------------------|-----------------------------|-----------------------------|
|                                     | n                   | n (%)                         | n (%)                       |                             |
| Sex                                 | Male                | 102                           | 93 (91.2)                   | 9 (8.8)                     | 0.332                       |
|                                     | Female              | 54                            | 52 (96.3)                   | 2 (3.7)                     |                             |
| Age                                 | <60 years old       | 108                           | 100 (92.6)                  | 8 (7.4)                     | 1.000                       |
|                                     | 60 and older        | 48                            | 45 (93.8)                   | 3 (6.3)                     |                             |
| Signs of pulmonary involvement      |                     |                               |                             |                             |
|                                    | O2 sat > 93% and CT ≤ 50% †   | 124                           | 121 (97.6)                  | 3 (2.4)                     | <0.001                      |
|                                    | O2 sat ≤ 93% or CT > 50%      | 32                            | 24 (75.0)                   | 8 (25.0)                    |                             |
| Obesity                             | No (BMI < 30 kg/m²)    | 75                            | 74 (98.7)                   | 1 (1.3)                     | 0.010                       |
|                                    | Yes (BMI ≥ 30 kg/m²)    | 81                            | 71 (87.7)                   | 10 (12.3)                   |                             |
| Diabetes                            | No                   | 116                           | 115 (99.1)                  | 1 (0.9)                     | <0.001                      |
|                                    | Yes                  | 40                            | 30 (75.0)                   | 10 (25.0)                   |                             |
| Asthma/COPD                         | No                   | 153                           | 142 (92.8)                  | 11 (7.2)                    | 1.000                       |
|                                    | Yes                  | 3                             | 3 (100.0)                   | 0 (0.0)                     |                             |
| Dyslipidemia                        | No                   | 131                           | 122 (93.1)                  | 9 (6.9)                     | 0.690                       |
|                                    | Yes                  | 25                            | 23 (92.0)                   | 2 (8.0)                     |                             |
| Coronary artery disease             | No                   | 153                           | 142 (92.8)                  | 11 (7.2)                    | 1.000                       |
|                                    | Yes                  | 3                             | 3 (100.0)                   | 0 (0.0)                     |                             |

BMI, body mass index; COPD, chronic obstructive pulmonary disease; CT, computed tomography; O2 sat, oxygen saturation on room air. * Modified World Health Organization (WHO) Ordinal Scale for Clinical Improvement scores of 6–8. † Extent of lung involvement on initial chest CT scan estimated by visual assessment performed by a radiologist.

All patients had non-severe COVID-19 (WHO scores of 3–5) on admission. Cough (62.2%), fever (57.1%), myalgia (47.4%), shortness of breath (44.2%), fatigue (43.6%), and headache (32.1%) were the most common symptoms at presentation (Figure S2). The mean interval from symptom onset to hospital presentation was 5.6 ± 3.1 days, and 19.2% of patients had ≤93% oxygen saturation on admission. On chest CT examinations, 59.6% of patients showed ≤25% lung involvement, 35.9% showed 26–50% involvement, and 4.5% showed >50% lung involvement. Thirty-two (20.5%) cases had significant pulmonary involvement (oxygen saturation ≤ 93% and/or >50% lung involvement on CT) at admission (Table S3).

3.1. Outcomes

Eleven (7.1%; 95% CI, 3.8–11.9%) patients progressed to severe disease during hospitalization, including three (1.9%) in-hospital deaths (Table S4). Progression to severe disease was associated with obesity (p = 0.010), diabetes (p < 0.001), and oxygen saturation ≤ 93% or lung involvement > 50% (p < 0.001) on admission, but not with age or sex (Table 1). Baseline patient characteristics and the most relevant comorbidities in patients that progressed or not to severe disease were presented in Table 1.
The mean hospital LOS was 9.1 ± 6.8 days. In total, 111 (71.2%) patients were admitted to the ICU; the mean ICU LOS was 7.6 ± 6.8 days (Table S5). According to the report on the BRACE-CORONA trial [21], the mean numbers of days spent alive and out of hospital did not differ among patients that were hospitalized with mild to moderate COVID-19, according to ACEI/ARB discontinuation or continuation. The most common complications were acute renal injury (8.3%), transient ischemic attack (4.5%), sepsis (3.8%), hemodynamic decompensation (3.2%), and hypertensive crisis (3.2%; Figure 1).

3.1. Outcomes
Eleven (7.1%; 95% CI, 3.8–11.9%) patients progressed to severe disease during hospitalization, including three (1.9%) in-hospital deaths (Table S4). Progression to severe disease was associated with obesity (p = 0.010), diabetes (p < 0.001), and oxygen saturation ≤ 93% or lung involvement >50% (p < 0.001) on admission, but not with age or sex (Table 1). Baseline patient characteristics and the most relevant comorbidities in patients that progressed or not to severe disease were presented in Table 1.

3.2. Immune Cell Profiles and Biomarkers
Blood samples were collected at a mean of 2.7 days after hospitalization. The mean CRP concentration and proportion of CD8+ T cells were elevated, and the total lymphocyte count was reduced in patients who progressed to severe disease (Table 2). Counts for all T-cell subsets were lower in the severe disease group; the reduced CD4+ T-cell count led to a reduction in the CD4/CD8 ratio. Patients who progressed to severe disease showed increases in the MFIs of HLA-DR and NKG2A in CD8+ T cells (Table 3). However, CD38 marker expression was similar in the two groups (Table 2).

The CRP concentration, total lymphocyte count, percentage of CD4+ T cells, and CD4/CD8 ratio were associated with disease progression (AUCs, 0.827, 0.702, 0.718, and 0.692, respectively). The percentage of CD8+ T cells and MFIs of HLA-DR and NKG2A in CD8+ T cells were also associated with disease progression (AUCs, 0.659, 0.670, and 0.650, respectively).

3.3. Predictive Model
The variables that were associated with disease progression in a preliminary univariate analysis were included in the initial model, namely diabetes, obesity, significant lung involvement on admission, the CRP concentration, and all cell subsets with AUCs ≥ 0.65 (Table 4).
Table 2. Biomarker levels according to disease progression (WHO score §).

| Biomarker                  | All (n = 156) | Non-Severe Cases † (n = 145) | Severe Cases ‡ (n = 11) |
|----------------------------|---------------|-------------------------------|------------------------|
| CRP, mg/L                  | Median 2.37   | Mean 4.62                     | SD 5.38               |
| Total lymphocyte count, ×10⁻⁶/L | Median 1395  | Mean 1521                     | SD 758                |
| Total monocyte count, ×10⁻⁶/L | Median 230   | Mean 369                      | SD 383                |
| Total B lymphocyte count, ×10⁻⁶/L | Median 107  | Mean 153                      | SD 161                |
| Total B lymphocytes %      | Median 8.0    | Mean 10.2                     | SD 8.5                |
| NK cell count, ×10⁻⁶/L      | Median 159    | Mean 199                      | SD 180                |
| NK cells, % *              | Median 10.8   | Mean 14.3                     | SD 11.2               |
| NK-NKG2A, % **            | Median 30.7   | Mean 34.1                     | SD 16.5               |
| NK-NKG2A MFI **           | Median 2.039  | Mean 2.209                    | SD 831                |
| Total T lymphocyte count, ×10⁻⁶/L | Median 78.0 | Mean 74.3                     | SD 14.8               |
| Total T lymphocytes, %     | Median 549    | Mean 651                      | SD 443                |
| CD4+ T cell count, ×10⁻⁶/L | Median 56.5   | Mean 54.8                     | SD 14.8               |
| CD8+ T cell count, ×10⁻⁶/L | Median 377    | Mean 433                      | SD 255                |
| CD8+ T cells, %            | Median 37.7   | Mean 39.0                     | SD 36.9               |
| CD4/CD8 *                  | Median 1.51   | Mean 1.76                     | SD 1.06               |
| CD8+ CD38+ T cells, % *   | Median 8.7    | Mean 14.4                     | SD 15.7               |
| CD8+ CD38+ T cells MFI *  | Median 4035   | Mean 4463                     | SD 2453               |
| CD8+ HLADR+ T cells, % *  | Median 15.3   | Mean 20.3                     | SD 18.8               |
| CD8+ HLADR+ T cells MFI * | Median 939    | Mean 1282                     | SD 944                |
| CD8+ NKG2A+ T cells, %    | Median 4.6    | Mean 8.0                      | SD 8.7                |
| CD8+ NKG2A+ T cells MFI   | Median 2153   | Mean 2154                     | SD 804                |
| CD8+ HLADR+ CD38- T cells, % * | Median 7.9 | Mean 14.2                     | SD 16.2               |
| CD8+ HLADR+ CD38- T cells MFI * | Median 3.6 | Mean 6.1                      | SD 6.7                |
| CD8+ HLADR- CD38- T cells, % * | Median 4.2   | Mean 8.3                      | SD 12.5               |
| CD8+ HLADR- CD38- T cells MFI * | Median 76.6 | Mean 71.4                     | SD 21.3               |

CRP, C-reactive protein; HLA-DR, human leukocyte antigen DR isotope; MFI, mean fluorescent intensity; NK, natural killer; NKG2A, natural killer group 2-member A. § Modified World Health Organization Ordinal Scale for Clinical Improvement. * Missing for one patient; ** missing for two patients. † Non-severe, scores of 3-5; ‡ Severe, scores of 6-8.

The four variables selected automatically for the final model were diabetes, significant lung involvement on admission, increased (above the 90% sensitivity threshold) CD8+ T-cell NKG2A MFI, and obesity. The adjusted ORs for the association of these clinical parameters with disease progression were 40.9 for diabetes, 13.3 for lung involvement and 13.8 for obesity (Table 4). In the presence of clinical comorbidities, increased (>2.054) CD8+ T-cell NKG2A MFI showed a strong capacity to predict disease progression (adjusted OR, 14.2; Figure 2 and Table 4). The estimated probability of progression to severe disease reached 86.2% in the presence of the four variables that were included in the model. The probabilities of COVID-19 progression according to the final logistic model are depicted in Table 5.
Table 3. Associations of biomarkers with disease progression by areas under ROC curves.

| Variables                        | Area under Curve | p-Value | Cut-off for 90% Sensitivity |
|----------------------------------|------------------|---------|----------------------------|
| CRP                              | 0.827            | <0.001  | 2.73                       |
| CD4+ T cells, % *                | 0.718            | 0.016   | 64.8                       |
| Total lymphocytes *              | 0.702            | 0.026   | 2100                       |
| CD4/CD8 *                        | 0.692            | 0.034   | 3.23                       |
| CD8+ HLA-DR T cell MFI           | 0.670            | 0.060   | 624                        |
| CD8+ T cells, %                  | 0.659            | 0.079   | 22.2                       |
| CD8+ NKG2A T cell MFI            | 0.650            | 0.097   | 2054                       |
| Monocytes                        | 0.644            | 0.112   |                            |
| B lymphocytes                    | 0.643            | 0.115   |                            |
| T lymphocytes                    | 0.636            | 0.132   |                            |
| NK cells                         | 0.601            | 0.265   |                            |
| CD8+ HLA-DR-CD38+ T cells       | 0.597            | 0.283   |                            |
| CD8+ CD38+ T cells              | 0.592            | 0.312   |                            |
| CD8+ HLA-DR+CD38+ T cells       | 0.585            | 0.350   |                            |
| NK-NKG2A cells                  | 0.570            | 0.438   |                            |
| NK-NKG2A cell MFI               | 0.567            | 0.459   |                            |
| CD8+ NKG2A+ T cells             | 0.554            | 0.549   |                            |
| CD8+ CD38+ T cell MFI           | 0.551            | 0.577   |                            |
| CD8+ HLA-DR-CD38- T cells       | 0.548            | 0.596   |                            |
| CD8+ HLA-DR+ T cells            | 0.541            | 0.651   |                            |
| CD8+ HLA-DR+CD38- T cells       | 0.534            | 0.707   |                            |

CRP, C-reactive protein; HLA-DR, human leukocyte antigen DR isotope; MFI, mean fluorescent intensity; NK, natural killer; NKG2A, natural killer group 2-member A. * For total lymphocytes, CD4+ T cells and CD4/CD8, reduced values are predictors of disease progression. ** Not calculated due to lack of statistical association at 10% significance level. Bold values indicate AUC ≥ 0.650.

Table 4. Forward stepwise logistic regression model for the prediction of COVID-19 progression to severe disease.

| Variables in the Equation | β   | p-Value | Odds Ratio |
|--------------------------|-----|---------|------------|
| Step 1                   |     |         |            |
| Diabetes                 | 3.64| 0.001   | 38.0       |
| Step 2                   |     |         |            |
| Diabetes                 | 3.37| 0.002   | 29.2       |
| Lung involvement †       | 2.29| 0.003   | 9.9        |
| Step 3                   |     |         |            |
| Diabetes                 | 3.74| 0.001   | 42.0       |
| Lung involvement         | 2.39| 0.006   | 10.9       |
| CD8+ NKG2A T cell MFI > 2054 | 2.78| 0.020 | 16.0       |
| Step 4                   |     |         |            |
| Diabetes                 | 3.71| 0.002   | 40.9       |
| Lung involvement         | 2.59| 0.008   | 13.3       |
| CD8+ NKG2A T cell MFI > 2054 | 2.65| 0.037   | 14.2       |
| Obesity                  | 2.63| 0.040   | 13.8       |

* Constant = −9.746; Hosmer–Lemeshow test, p = 0.948. † Significant lung involvement (oxygen saturation ≤ 93% or >50% lung involvement on computed tomography examination) on admission. MFI, mean fluorescent intensity; NKG2A, natural killer group 2 member A.
Figure 2. Model for the prediction of the risk of COVID-19 progression in the presence of increased CD8+ T-cell NKG2A MFI and clinical variables. HLA-DR, human leukocyte antigen DR isotope; mAb, monoclonal antibody; MFI, mean fluorescent intensity; NKG2A, natural killer group 2-member A.

Table 5. Probabilities of COVID-19 progression according to the final logistic model.

| CD8+ NKG2A T Cell MFI | ≤2054 * | >2054 |
|------------------------|---------|-------|
| No clinical risk factor † | 0.0% | 0.1% |
| Diabetes only | 0.2% | 3.3% |
| Obesity only | 0.1% | 1.1% |
| Lung involvement only ‡ | 0.1% | 1.1% |
| Diabetes + obesity | 3.2% | 31.9% |
| Diabetes + lung involvement | 3.1% | 31.1% |
| Obesity + lung involvement | 1.1% | 13.2% |
| Diabetes + obesity + lung involvement | 30.6% | 86.2% |

* Cut-off for 90% sensitivity. † Clinical risk factors included in the model are diabetes, obesity, and significant lung involvement on admission. ‡ Oxygen saturation ≤ 93% or >50% lung involvement on computed tomography examination. MFI, mean fluorescent intensity; NKG2A, natural killer group 2 member A.

4. Discussion

Our study investigated the association of the key immune cell profile with disease progression in patients with hypertension who required hospitalization for COVID-19. The main findings can be summarized as follows: (i) reduced total lymphocyte count, CD4+ and CD8+ T cell count and CD4/CD8 ratio; and increased CD8+ HLA-DR MFI, and CD8+ NKG2A MFI on admission, were associated with progression to severe COVID-19; (ii) according to our logistic regression model, increased CD8+ NKG2A MFI at hospital admission, in combination with some clinical variables, including obesity and diabetes, is associated with a high risk of COVID-19 progression in these patients.

Clinical comorbidities, particularly diabetes, hypertension, and obesity, have been associated with COVID-19 severity in several studies, as we discussed in a previous
A chest CT examination has also been proposed for the prediction of clinical outcomes of COVID-19 [23,24]. In our previous study, we demonstrated that interleukin-10 and interleukin-12 (p70) levels, in combination with clinical variables, at hospital admission are key biomarkers associated with an increased risk of disease progression in hypertensive patients with COVID-19, and we proposed a biomarker-based approach to improve the prediction of this risk [11]. In this study, to improve the understanding of the associations of clinical variables and immune cell profiles with the risk of COVID-19 progression, we also used a forward stepwise predictive model, which combined immune cell subsets with clinical variables to predict the probability of progression to severe COVID-19.

Similar to our findings, several authors have reported reduced populations of lymphocytes, including T, B, and NK cells, and increased neutrophil counts in blood in patients with COVID-19, with more pronounced changes seen in severe cases [12,15,16,25,26]. Cell-mediated immunity plays a vital role in the immune response against viral infections, and interactions between the innate and adaptive immune systems are key parts of an effective host response. The functional impairment of cytotoxic lymphocytes and NK cells is associated with SARS-CoV-2 persistence [26].

Zheng et al. [17] proposed that COVID-19 progression is related to the functional exhaustion of T cells with the increased expression of NKG2A. NKG2A is an inhibitory receptor that can induce NK and T cell exhaustion, suppressing the cytotoxic activity of these immune cells and promoting viral spread during a variety of chronic viral infections [27,28]. Cytokine levels of IL-6 and IL-10, which are markedly increased in patients with COVID-19, can elicit the upregulation of NKG2A expression, potentializing its inhibitory role [25]. We previously observed increased levels of these cytokines in hypertensive patients with COVID-19 progression to severe disease [11]. Cho et al. showed that IL-6 and IL-10 enhanced CD94/NKG2A expression in naive CD8+ T cells [29], and different authors have demonstrated that higher levels of IL-10 are associated with increased NKG2A expression in viral infections [30–32]. In line with these findings, our results showed that in hypertensive patients, NKG2A also emerges as an important feature in patients with COVID-19 who progressed to severe disease.

The immune cell profile that was observed in this study corroborates the hypothesis that COVID-19 progression is related to T-cell exhaustion with increased NKG2A expression. These findings contribute to our understanding of how SARS-CoV-2 infection may break down the antiviral immune response at an early stage through this mechanism. These immune cell subsets might be useful for a better understanding and prediction of the progression to severe COVID-19. These findings are relevant, as they support the potential use of the anti-NKG2A monoclonal antibody monalizumab in patients with COVID-19. The use of this drug to control tumor growth by restoring CD8+ T and NK cell functions is currently under investigation [19]; phase-2 clinical trials have revealed no significant side effects [16,33].

This study has some limitations. Blood samples were collected at a mean of 2.7 days after hospitalization, and the median interval between symptom onset and hospital admission was 5.0 days. In addition, our population consisted only of hypertensive patients taking ACEIs/ARBs; the exclusion of patients with severe hypertension and high-risk clinical presentations (i.e., hemodynamic instability or mechanical ventilation requirement on admission) may limit the generalizability of our results. Still, the widespread use of ACEIs/ARBs in the hypertensive population and the multicentric nature of the study might help to ensure the good external validity of the findings. Patients’ previous use of glucocorticoids could have affected our analysis; however, only five (3.2%) of the patients were using this drug before hospitalization. Additional studies are needed to validate the results that were obtained in this work in more heterogeneous populations of hypertensive patients and to evaluate the applicability of the proposed model to non-hypertensive COVID-19 populations.
5. Conclusions

This study demonstrated that increased NKG2A expression among CD8 cells, in combination with some clinical variables (obesity, diabetes, and extensive lung involvement), could become a biomarker of COVID-19 progression. These findings reinforce the hypothesis that T-cell exhaustion, characterized by increased NKG2A expression, is a crucial mechanism of breaking the antiviral immune response in COVID-19. These data may have direct therapeutic implications for the future.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm11133713/s1, Table S1: Disease severity according to modified WHO scores; Table S2: Antibodies used for cell staining; Table S3: Degrees of lung involvement on admission; Table S4: Progression to severe disease according to WHO scores; Table S5: LOS in the hospital and ICU; Figure S1: Comorbidities at admission (%); Figure S2: Symptoms at presentation (%).

Reference [22] is cited in the supplementary materials.

Author Contributions: Conceptualization, R.M.-B., E.M., A.S.S., F.A.B. and R.R.L.; methodology, S.C.F., N.V., L.C., M.C.-C., E.M. and F.A.S.; software, R.R.L.; validation, F.A.B. and R.D.L.; formal analysis, R.R.L.; investigation, A.F., G.A., K.G., T.C.P., T.F., V.A.L., N.O., A.M., P.B.e.S., F.D.L., M.K. and R.D.; resources, R.M.-B., E.M., A.S.S., D.C.A. and O.F.S.; data curation, F.A.B. and M.F.S.; writing—original draft preparation, R.M.-B.; writing—review and editing, E.M., A.S.S. and F.A.B.; visualization, O.F.S.; supervision, E.M.; project administration, R.M.-B., E.M. and M.F.S.; funding acquisition, R.M.-B., E.M., A.S.S. and O.F.S. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by intramural grants from the D’Or Institute of Research and Education; the Brazilian Clinical Research Institute; the Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (nos. E-26/210.155/2020, E-26/203.169/2017, E-26/210.191/2020, and E-26/210.253/2020); the CNPq (no. 310681/2018-9); CAPES; FINEP; and the Serrapilheira Institute.

Institutional Review Board Statement: The study protocol was approved by the Brazilian Ministry of Health’s National Commission for Research Ethics (CAAE # 30432020.2.0000.5249) and adhered to the ethical principles of the Declaration of Helsinki, specifications of the International Council for Harmonization, and good clinical practice.

Informed Consent Statement: All patients provided informed consent before study procedure initiation.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.

Acknowledgments: We thank all the staff and research assistants from the D’Or Institute of Research and Education (IDOR); the Brazilian Clinical Research Institute (BCRI); and Rede D’Or Hospitals who took part in this study. In addition, the authors thank all patients for agreeing to participate in this project.

Conflicts of Interest: Lopes reports receiving grant support from Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Sanofi, and Pfizer, and consulting fees from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, Sanofi, and Portola. Macedo reports receiving consulting fees from Pfizer, Bayer, AstraZeneca, Novartis, Daiichi-Sankyo, Zodiac, Roche, and Janssen. Feldman reports receiving consulting fees from Pfizer, Bayer, Daiichi-Sankyo, Boehringer, and Servier. D’Andrea Saba Arruda reports receiving consulting fees from Bayer, Pfizer, Servier, AstraZeneca, and Daiichi Sankyo. Albuquerque reports receiving consulting fees from Boehringer Ingelheim, AstraZeneca, and Daiichi Sankyo. Souza reports receiving consulting fees from Boehringer Ingelheim and consulting fees from Pfizer, Bayer, Daiichi-Sankyo, and Boehringer Ingelheim. The authors have no other disclosure to report.
References

1. Peng, M.; He, J.; Xue, Y.; Yang, X.; Liu, S.; Gong, Z. Role of Hypertension on the Severity of COVID-19: A Review. J. Cardiovasc. Pharmacol. 2021, 78, e648. [CrossRef] [PubMed]

2. Palaiodimos, L.; Ali, R.; Teo, H.O.; Parthasarathy, S.; Karamanis, D.; Chamorro-Pareja, N.; Kokkinidis, D.G.; Kaur, S.; Kladas, M.; Sperling, J. Obesity, Inflammation, and Mortality in COVID-19: An Observational Study from the Public Health Care System of New York City. J. Clin. Med. 2022, 11, 622. [CrossRef] [PubMed]

3. Palaiodimos, L.; Chamorro-Pareja, N.; Karamanis, D.; Li, W.; Zavras, P.D.; Chang, K.M.; Mathias, P.; Kokkinidis, D.G. Diabetes is associated with increased risk for in-hospital mortality in patients with COVID-19: A systematic review and meta-analysis comprising 18,506 patients. Hormones 2021, 20, 305–314. [CrossRef] [PubMed]

4. Palaiodimos, L.; Kokkinidis, D.G.; Li, W.; Karamanis, D.; Ognibene, J.; Arora, S.; Southern, W.N.; Mantzoros, C.S. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism 2020, 108, 154262. [CrossRef]

5. Guerson-Gil, A.; Palaiodimos, L.; Assa, A.; Karamanis, D.; Kokkinidis, D.; Chamorro-Pareja, N.; Kishore, P.; Leider, J.M.; Brandt, L.J. Sex-specific impact of severe obesity in the outcomes of hospitalized patients with COVID-19: A large retrospective study from the Bronx, New York. Eur. J. Clin. Microbiol. Infect. Dis. 2021, 40, 1963–1974. [CrossRef]

6. Norlander, A.E.; Madhur, M.S.; Harrison, D.G. The immunology of hypertension. J. Exp. Med. 2018, 215, 21–33. [CrossRef]

7. Caillon, A.; Schiffrin, E.L. Role of inflammation and immunity in hypertension: Recent epidemiological, laboratory, and clinical evidence. Curr. Hypertens. Rep. 2016, 18, 1–9. [CrossRef]

8. Mehta, P.; McAuley, D.F.; Brown, M.; Sanchez, E.; Tattersall, R.S.; Manson, J.J. COVID-19: Consider cytokine storm syndromes and immunosuppression. The Lancet. 2020, 395, 1033–1034. [CrossRef]

9. Lowenstein, C.J.; Solomon, S.D. Severe COVID-19 is a microvascular disease. Circulation 2020, 142, 1609–1611. [CrossRef]

10. Wan, S.; Yi, Q.; Fan, S.; Lv, J.; Zhang, X.; Guo, L.; Lang, C.; Xiao, Q.; Xiao, K.; Yi, Z. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus COVID-19 infected patients. Br. J. Haematol. 2020, 189, 428–437. [CrossRef]

11. Moll-Bernardes, R.; De Sousa, A.S.; Macedo, A.V.S.; Lopes, R.D.; Vera, N.; Maia, L.C.R.; Feldman, A.; Arruda, G.; Castro, M.J.C.; Pimentel-Celho, P.M. IL-10 and IL-12 (P70) Levels Predict the Risk of COVID-19 Progression in Hypertensive Patients: Insights From the BRACE-CORONA Trial. Front. Cardiovasc. Med. 2021, 18, 820. [CrossRef] [PubMed]

12. Varchetta, S.; Mele, D.; Oliviero, B.; Mantovani, S.; Ludovisi, S.; Cerino, A.; Bruno, R.; Castelli, A.; Mosconi, M.; Vecchia, M.; et al. Unique immunological profile in patients with COVID-19. Cell Mol. Immunol. 2020, 18, 604–612. [CrossRef] [PubMed]

13. Chen, G.; Wu, D.; Guo, W.; Cao, Y.; Huang, D.; Wang, H.; Wang, T.; Zhang, X.; Chen, H.; Yu, H.; et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J. Clin. Invest. 2020, 130, 2620–2629. [CrossRef] [PubMed]

14. Del Valle, D.M.; Kim-Schulze, S.; Huang, H.H.; Beckmann, N.D.; Nirenberg, S.; Wang, B.; Lavin, Y.; Swartz, T.H.; Madduri, D.; Stock, A.; et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat. Med. 2020, 26, 1636–1643. [CrossRef]

15. Qin, C.; Zhou, L.; Hu, Z.; Zhang, S.; Yang, S.; Tao, Y.; Xie, C.; Ma, K.; Shang, K.; Wang, W. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 2020, 71, 762–768. [CrossRef] [PubMed]

16. Yaqinuddin, A.; Kashir, J. Innate immunity in COVID-19 patients mediated by NKG2A receptors, and potential treatment using Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. Mol. Immunol. 2018, 15, 33–41. [CrossRef] [PubMed]

17. Zheng, M.; Gao, Y.; Song, G.; Liu, S.; Sun, D.; Xu, Y.; Tian, Z. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell. Mol. Immunol. 2017, 14, 305–314. [CrossRef] [PubMed]

18. Andrie, P.; Denis, C.; Soulas, C.; Bourbon-Caillet, C.; Lopez, J.; Arnoux, T.; Blery, M.; Bonafo, C.; Gauthier, L.; Morel, A. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. Mol. Immunol. 2018, 15, 1731–1743.e1713. [CrossRef]

19. Peng, M.; He, J.; Xue, Y.; Yang, X.; Liu, S.; Gong, Z. Role of Hypertension on the Severity of COVID-19: A Review. J. Cardiovasc. Pharmacol. 2021, 78, e648. [CrossRef] [PubMed]

20. Lopes, R.D.; Macedo, A.V.S.; de Barros, E.S.P.M.; Moll-Bernardes, R.J.; Feldman, A.; D’Andrea Saba Arruda, G.; de Souza, A.S.; de Albuquerque, D.C.; Mazza, L.; Santos, M.F.; et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–The BRACE-CORONA Trial. Am. Heart J. 2020, 226, 49–59. [CrossRef] [PubMed]

21. Lopes, R.D.; Macedo, A.V.S.; de Barros, E.S.P.M.; Moll-Bernardes, R.J.; Dos Santos, T.M.; Mazza, L.; Feldman, A.; D’Andrea Saba Arruda, G.; de Albuquerque, D.C.; Camiletti, A.S.; et al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. JAMA 2021, 325, 254–264. [CrossRef]

22. World, H.O. WHO R&D Blueprint: COVID-19 Therapeutic Trial Synopsis. Published February. 2020. Available online: https://www.who.int/blueprint/priority-diseases/key-action/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdf (accessed on 20 October 2020).

23. Francone, M.; Iafrate, F.; Masci, G.M.; Coco, S.; Cilia, F.; Manganaro, L.; Panebianco, V.; Andreoli, C.; Colaiacomo, M.C.; Zingaropoli, M.A.; et al. Chest CT score in COVID-19 patients: Correlation with disease severity and short-term prognosis. European Radiology. 2020, 30, 6808–6817. [CrossRef] [PubMed]
24. Yang, R.; Li, X.; Liu, H.; Zhen, Y.; Zhang, X.; Xiong, Q.; Luo, Y.; Gao, C.; Zeng, W. Chest CT severity score: An imaging tool for assessing severe COVID-19. *Radiol. Cardiothorac. Imaging* 2020, 2, e200047. [CrossRef] [PubMed]

25. Antonioli, L.; Fornai, M.; Pellegrini, C.; Blandizzi, C. NKG2A and COVID-19: Another brick in the wall. *Cell. Mol. Immunol.* 2020, 17, 672–674. [CrossRef] [PubMed]

26. Taefehshokr, N.; Taefehshokr, S.; Hemmat, N.; Heit, B. COVID-19: Perspectives on innate immune evasion. *Front. Immunol.* 2020, 11, 580641. [CrossRef] [PubMed]

27. Li, F.; Wei, H.; Wei, H.; Gao, Y.; Xu, L.; Yin, W.; Sun, R.; Tian, Z. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice. *Gastroenterology* 2013, 144, 392–401. [CrossRef]

28. Zhang, C.; Wang, X.-m.; Li, S.-r.; Twelkmeyer, T.; Wang, W.-h.; Zhang, S.-y.; Wang, S.-f.; Chen, J.-z.; Jin, X.; Wu, Y.-z. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. *Nat. Commun.* 2019, 10, 1–11. [CrossRef]

29. Cho, J.-H.; Kim, H.-O.; Webster, K.; Palendira, M.; Ahm, B.; Kim, K.-S.; King, C.; Tangye, S.G.; Sprent, J. Calcineurin-dependent negative regulation of CD94/NKG2A expression on naive CD8+ T cells. *Blood J. Am. Soc. Hematol.* 2011, 118, 116–128. [CrossRef]

30. Jinushi, M.; Takehara, T.; Tatsumi, T.; Kanto, T.; Miyagi, T.; Suzuki, T.; Kanazawa, Y.; Hiramatsu, N.; Hayashi, N. Negative regulation of NK cell activities by inhibitory receptor CD94/NKG2A leads to altered NK cell-induced modulation of dendritic cell functions in chronic hepatitis C virus infection. *J. Immunology.* 2004, 173, 6072–6081. [CrossRef]

31. Ma, Q.; Dong, X.; Liu, S.; Zhong, T.; Sun, D.; Zong, L.; Zhao, C.; Lu, Q.; Zhang, M.; Gao, Y. Hepatitis B e antigen induces NKG2A+ natural killer cell dysfunction via regulatory T cell-derived interleukin 10 in chronic hepatitis B virus infection. *Front. Cell Dev. Biol.* 2020, 8, 421. [CrossRef]

32. Sun, C.; Xu, J.; Huang, Q.; Huang, M.; Wen, H.; Zhang, C.; Wang, J.; Song, J.; Zheng, M.; Sun, H. High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer. *Oncoimmunology* 2017, 6, e1264562. [CrossRef] [PubMed]

33. Creelan, B.C.; Antonia, S.J. The NKG2A immune checkpoint—A new direction in cancer immunotherapy. *Nat. Rev. Clin. Oncol.* 2019, 16, 277–278. [CrossRef] [PubMed]